Vertex Pharmaceuticals has agreed to acquire San Diego-based Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) for USD 85.00 per share in cash, representing a total equity value of approximately USD 10.0 billion, or USD 8.8 billion net of estimated cash acquired. The acquisition gives Vertex an immediately commercial rare endocrine therapy alongside a Phase III pipeline candidate with multi-billion-dollar sales potential, representing the company's largest strategic expansion beyond cystic fibrosis.
Vertex will finance the acquisition using cash on hand and debt, supported by USD 4.5 billion in committed bridge financing. The deal is expected to close in Q3 2026, subject to regulatory approvals and Crinetics shareholder approval.
The commercial anchor of the deal is Palsonify (paltusotine), the first and only once-daily oral somatostatin receptor type 2 (SST2) nonpeptide agonist approved for adults with acromegaly with inadequate response to surgery or for whom surgery is not an option. The US FDA approved paltusotine in September 2025, and the European Commission granted approval in April 2026. Paltusotine selectively binds SST2 receptors to suppress excess growth hormone and insulin-like growth factor-1 (IGF-1) secretion, offering a differentiated oral alternative to the large-needle intramuscular or deep subcutaneous injectable somatostatin analogues that have historically dominated acromegaly management.
Early commercial uptake has been encouraging, with Crinetics reporting more than USD 5 million in Q4 2025 net product revenue, over 200 enrollment forms, and more than 125 unique prescribers. Paltusotine also enjoys first-mover status as the only approved oral therapy in the class. Sweden-based Camurus's injectable candidate CAM2029 (oclaiz), which targets the same indication, has received repeated FDA complete response letters linked to manufacturing deficiencies, leaving paltusotine without an approved oral or next-generation injectable competitor in the near term.
The second strategic asset is atumelnant, a once-daily oral ACTH receptor antagonist that acts selectively at the melanocortin type 2 receptor (MC2R) in the adrenal cortex. By directly antagonizing the ACTH receptor, atumelnant inhibits downstream androgen and glucocorticoid production irrespective of ACTH origin, enabling sustained androgen normalization in classic congenital adrenal hyperplasia (CAH) even as glucocorticoid doses are reduced to physiologic replacement levels. Atumelnant is currently enrolling the Phase III CALM-CAH trial in adults and a Phase II/III BALANCE-CAH study in pediatric patients. A Phase I/IIb trial in ACTH-dependent Cushing's syndrome is also enrolling.